Breast Cancer Diagnostics Market
Breast Cancer Diagnostics Market Analysis by Test Type (CA Tests, BRCA Test, ER & PR Test, CEA Test, KRAS Mutation Test, HER 2 Test, PSA Test, EGFR Mutation Test, Immunohistochemistry for Breast Cancer), by End-User & Region - Global Forecast 2022 to 2032
Analysis of Breast Cancer Diagnostics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Global Breast Cancer Diagnostics Market Outlook (2022 to 2032)
The global breast cancer diagnostics market is likely to acquire a market value of US$ 4 Bn in 2022 and is expected to register a CAGR of 7% by accumulating a market value of US$ 7.9 Bn in the forecast period 2022 to 2032.
| Report Attributes | Details |
|---|---|
| Market Size Value in 2022 | US$ 4 Bn |
| Project Market Forecast Value in 2032 | US$ 7.9 Bn |
| Global Growth Rate (2022-2032) | 7% |
| Market Share of North America | 45% |
| Key Companies Profiled | Bio-Rad Laboratories Inc.; Illumina Inc.; Biocept Inc.; Epigenomics AG; AstraZeneca plc; Myriad Genetics Inc.; Quest Diagnostics Incorporated. |
Increasing prevalence of breast cancer, reoccurrence of the same and availability of different test is positively influencing the demand for breast cancer diagnostics. Moreover, growing inclination towards early detection of breast cancer diagnosis is driving the demand for breast cancer diagnostics.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Demand Analysis of Breast Cancer Diagnostics from 2017 to 2021 Vs Market Projections for 2022 to 2032
As per Fact.MR’s report, from 2017 to 2021, the global breast cancer diagnostics domain experienced an uptick at around 6% CAGR. Rising prevalence of malignant genes amongst women across generations and fear of passing on the same gene across families led to an increase in the service.
In 2021, WHO stated that, globally, breast cancer is the most common type of cancer, with as much as more than 2.3 Million new cases being recorded. This increasing instance of breast cancer is largely shaping demand for early breast cancer diagnosis. Rising awareness about breast cancer via various government initiatives and various cancer organizations is boosting market growth.
Screening procedures temporarily dwindled during the worst of the COVID-19 pandemic. As healthcare providers raced to accommodate the exponentially rising caseloads, other diagnostic procedures were put on hold. However, as the incidence receded, prospects rebounded. From 2022 to 2032, breast cancer diagnostics are expected to surpass US$ 7.9 Bn by registering a CAGR of 7% in the assessment period.
Early Detection Bolstering Demand for Breast Cancer Diagnostics?
The number of breast cancer cases across the globe is rising rapidly and has become the most common type of cancer in 2021. Early detection of breast cancer tumours is one of the major challenges in diagnosis and treatment, as in most cases, they are detected after they have grown to an advanced stage.
Demand for early detection of breast cancer is seeing a major rise as people are seeking more efficient diagnostic solutions to deal with the disease effectively. Apart from other tests to detect breast cancer, imaging and screening have also seen substantial rise in popularity. Screening for breast cancer is deemed effective, but some methods are still being debated whether they are safe and accurate for prolonged use.
Breast cancer diagnostic PCR tests, biopsy for breast cancer diagnostics, and application of microarray in breast cancer diagnostics are some of the trends that are expected to be witnessed over the decade.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Different Testing Method Creating Lucrative Opportunities for Breast Cancer Diagnostics?
As research on the detection of breast cancer increases, new and innovative diagnostic methods are being adopted and applied. Most of these methods are not used extensively, but as research is backing their credibility, these methods are expected to become mainstream over the years.
- Diagnostic Imaging for Breast Cancer
- Biopsy Procedure for Breast Cancer Diagnostics
- Genomic Tests for Breast Cancer Diagnostics
- Blood Tests for Breast Cancer Diagnostics
- Next-generation Sequencing for Breast Cancer Diagnostics
- Microarrays in breast cancer diagnostics
Imaging is the most prominent and widely used among these. Demand for genomic tests in breast cancer diagnostics, demand for next-generation sequencing in breast cancer diagnostics, and demand for blood tests in breast cancer diagnostics are relatively low in comparison to imaging due to lack of research to back their credibility, accuracy, and in some cases, even affordability.
Breast biopsy for breast cancer diagnostics is anticipated to see a steady rise in popularity over the decade.
Country-wise Analysis
Well-Established Diagnostics Centres Creating Lucrative Opportunities in North America?
Demand for breast cancer diagnostics in the U.S. is anticipated to increase at a high CAGR owing to rising cases across the nation. Well-established diagnostic infrastructure, technological advancements, increasing healthcare expenditure, and rising awareness about breast cancer are some of the prime factors that are shaping market growth in the country.
Thus, North America is anticipated to account for more than 45% of global breast cancer diagnostics market share in the forecast period 2022-2032.
Affordability Driving Demand for Breast Cancer Diagnostics across Asia Pacific?
Demand in the APAC region is expected to be driven by nations such as China and India, where instances of breast cancer are increasing. Demand for breast cancer diagnostics at independent diagnostic laboratories in the APAC region is expected to see an increase as breast cancer diagnosis instruments become more affordable.
Moreover, the number of women diagnosed with breast cancer has been increasing in India, and this is common across rural as well as urban areas. Breast cancer accounts for nearly 14% of all cancers found in Indian women. In addition, rising instances of cancer is driving demand for early breast cancer diagnostics in the nation. Development of affordable and cost-effective diagnostic solutions is a major factor influencing demand in India. Thus, Asia Pacific is expected to account for more than 40% market share for breast cancer diagnostics market growth through 2032.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-Wise Insights
Biopsy Procedure Surging Demand Treatment in Hospital associated Labs?
Rising hospitalization of patients, increasing instances of breast cancer, and rise in demand for biopsy procedure in breast cancer diagnostics are some of the prime factors driving the hospital-associated labs segment.
Thus, adoption of breast cancer diagnostics at hospital-associated labs is high and is expected to account for nearly 50% revenue share of the global market in 2032.
Are Patients Favouring CEA Tests Due to its Accuracy?
As research to find better diagnostic solutions increases, so will demand for breast cancer diagnostics at cancer research institutes. Innovative and early diagnostics solutions for breast cancer are constantly being researched on and the trend is expected to be prevalent through the decade.
Demand for CEA tests for breast cancer is anticipated to witness the highest CAGR. This is due to the test’s capacity to check the probability of reoccurrence of cancer cells. Thus, inclination towards CEA test has increased in recent years. Due to the reasons mentioned above, CEA test are expected to hold more than 45% market share for Breast Cancer Diagnostics.
Competitive Landscape
Prime providers of breast cancer diagnostics are striving to come up with diagnostic solutions that offer early detection of breast cancer. Key market players are also investing in the research & development of diagnostic solutions that are fast, accurate, and cost-efficient.
- Vice President of India, Shri M. Venkaiah Naidu, in September 2021, launched the first-of-its-kind breast cancer helpline, set up by the Ushalakshmi Breast Cancer Foundation. This is a new step for the nation to spread awareness about breast cancer.
- Elizabeth Hurley, actress and model, launched a cancer support center in London in September 2021, ahead of the cancer awareness month. The support centre was named Future Dreams House.
- In October 2021, to increase awareness about breast cancer, WellSpan Health and Capital Blue Cross, in collaboration, launched a mobile mammography motor coach, which is in accordance with their goal to increase screening for breast cancer across five countries.
Key Segments Covered in the Breast Cancer Diagnostics Report
-
By Test Type
- CA Tests for Breast Cancer
- BRCA Test for Breast Cancer
- ER & PR Test for Breast Cancer
- CEA Test for Breast Cancer
- KRAS Mutation Test for Breast Cancer
- HER 2 Test for Breast Cancer
- PSA Test for Breast Cancer
- EGFR Mutation Test for Breast Cancer
- Immunohistochemistry for Breast Cancer
- Others
-
By End User
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Cancer Research Institutes
- Others
Table of Content
- 1. Global Market to Executive Summary
- 2. Global Market Overview
- 3. Global Market Analysis and Forecast By Test Type
- 3.1. BRCA
- 3.2. ER & PR
- 3.3. CEA
- 3.4. KRAS Mutation
- 3.5. HER 2
- 3.6. PSA
- 3.7. CA Test
- 3.8. EGFR Mutation Test
- 3.9. Immunohistochemistry
- 3.10. Others
- 4. Global Market Analysis and Forecast By End User
- 4.1. Hospital Associated Labs
- 4.2. Independent Diagnostic Laboratories Breast Cancer
- 4.3. Cancer Research Institutes Breast Cancer
- 4.4. Others
- 5. Global Market Analysis and Forecast By Region
- 5.1. North America
- 5.2. Latin America
- 5.3. Europe
- 5.4. Japan
- 5.5. APEJ
- 5.6. MEA
- 6. North America Market Analysis and Forecast, By Country, 2017 to 2032
- 7. Latin America Market Analysis and Forecast, By Country, 2017 to 2032
- 8. Europe Market Analysis and Forecast, By Country, 2017 to 2032
- 9. Japan Market Analysis and Forecast, By Country, 2017 to 2032
- 10. APEJ Market Analysis and Forecast, By Country, 2017 to 2032
- 11. MEA Market Analysis and Forecast, By Country, 2017 to 2032
- 12. Company Profiles
- 12.1. Abbott Laboratories
- 12.2. Roche Holding AG
- 12.3. Thermo Fisher Scientific Inc.
- 12.4. Siemens AG
- 12.5. Bio-Rad Laboratories, Inc.
- 12.6. Illumina, Inc.
- 12.7. Biocept, Inc.
- 12.8. AstraZeneca plc
- 12.9. Myriad Genetics Inc
- 12.10. Quest Diagnostics Incorporated
- 13. Disclaimer and Contact Information
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
TABLE 1: Global Market Value (US$ Mn), 2017 to 2021
TABLE 2: Global Market Value (US$ Mn), 2022 to 2032
TABLE 3: Global Market Value (US$ Mn) and Y-o-Y, 2017 to 2032 Value (US$ Mn)
TABLE 4: Global BRCA Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 5: Global BRCA Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 6: Global BRCA Segment Market Share, By Region 2017 to 2021
TABLE 7: Global BRCA Segment Market Share, By Region 2022 to 2032
TABLE 8: Global BRCA Segment Y-o-Y, By Region 2017 to 2032
TABLE 9: Global ER & PR Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 10: Global ER & PR Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 11: Global ER & PR Segment Market Share, By Region 2017 to 2021
TABLE 12: Global ER & PR Segment Market Share, By Region 2022 to 2032
TABLE 13: Global ER & PR Segment Y-o-Y, By Region 2017 to 2032
TABLE 14: Global CEA Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 15: Global CEA Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 16: Global CEA Segment Market Share, By Region 2017 to 2021
TABLE 17: Global CEA Segment Market Share, By Region 2022 to 2032
TABLE 18: Global CEA Segment Y-o-Y, By Region 2017 to 2032
TABLE 19: Global KRAS Mutation Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 20: Global KRAS Mutation Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 21: Global KRAS Mutation Segment Market Share, By Region 2017 to 2021
TABLE 22: Global KRAS Mutation Segment Market Share, By Region 2022 to 2032
TABLE 23: Global KRAS Mutation Segment Y-o-Y, By Region 2017 to 2032
TABLE 24: Global HER 2 Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 25: Global HER 2 Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 26: Global HER 2 Segment Market Share, By Region 2017 to 2021
TABLE 27: Global HER 2 Segment Market Share, By Region 2022 to 2032
TABLE 28: Global HER 2 Segment Y-o-Y, By Region 2017 to 2032
TABLE 29: Global PSA Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 30: Global PSA Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 31: Global PSA Segment Market Share, By Region 2017 to 2021
TABLE 32: Global PSA Segment Market Share, By Region 2022 to 2032
TABLE 33: Global PSA Segment Y-o-Y, By Region 2017 to 2032
TABLE 34: Global CA Test Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 35: Global CA Test Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 36: Global CA Test Segment Market Share, By Region 2017 to 2021
TABLE 37: Global CA Test Segment Market Share, By Region 2022 to 2032
TABLE 38: Global CA Test Segment Y-o-Y, By Region 2017 to 2032
TABLE 39: Global EGFR Mutation Test Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 40: Global EGFR Mutation Test Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 41: Global EGFR Mutation Test Segment Market Share, By Region 2017 to 2021
TABLE 42: Global EGFR Mutation Test Segment Market Share, By Region 2022 to 2032
TABLE 43: Global EGFR Mutation Test Segment Y-o-Y, By Region 2017 to 2032
TABLE 44: Global Immunohistochemistry Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 45: Global Immunohistochemistry Segment Value (US$ Mn), By Region 2022 to 2032MEA
TABLE 46: Global Immunohistochemistry Segment Market Share, By Region 2017 to 2021
TABLE 47: Global Immunohistochemistry Segment Market Share, By Region 2022 to 2032
TABLE 48: Global Immunohistochemistry Segment Y-o-Y, By Region 2017 to 2032
TABLE 49: Global Others Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 50: Global Others Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 51: Global Others Segment Market Share, By Region 2017 to 2021
TABLE 52: Global Others Segment Market Share, By Region 2022 to 2032
TABLE 53: Global Others Segment Y-o-Y, By Region 2017 to 2032
TABLE 54: Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 55: Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 56: Global Hospital Associated Labs Segment Market Share, By Region 2017 to 2021
TABLE 57: Global Hospital Associated Labs Segment Market Share, By Region 2022 to 2032
TABLE 58: Global Hospital Associated Labs Segment Y-o-Y, By Region 2017 to 2032
TABLE 59: Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 60: Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 61: Global Independent Diagnostic Laboratories Segment Market Share, By Region 2017 to 2021
TABLE 62: Global Independent Diagnostic Laboratories Segment Market Share, By Region 2022 to 2032
TABLE 63: Global Independent Diagnostic Laboratories Segment Y-o-Y, By Region 2017 to 2032
TABLE 64: Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 65: Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 66: Global Cancer Research Institutes Segment Market Share, By Region 2017 to 2021
TABLE 67: Global Cancer Research Institutes Segment Market Share, By Region 2022 to 2032
TABLE 68: Global Cancer Research Institutes Segment Y-o-Y, By Region 2017 to 2032
TABLE 69: Global Others Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 70: Global Others Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 71: Global Others Segment Market Share, By Region 2017 to 2021
TABLE 72: Global Others Segment Market Share, By Region 2022 to 2032
TABLE 73: Global Others Segment Y-o-Y, By Region 2017 to 2032
TABLE 74: North America Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 75: North America Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 76: North America Market Value (US$ Mn), By End User 2017 to 2021
TABLE 77: North America Market Value (US$ Mn), By End User 2022 to 2032
TABLE 78: Latin America Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 79: Latin America Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 80: Latin America Market Value (US$ Mn), By End User 2017 to 2021
TABLE 81: Latin America Market Value (US$ Mn), By End User 2022 to 2032
TABLE 82: Europe Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 83: Europe Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 84: Europe Market Value (US$ Mn), By End User 2017 to 2021
TABLE 85: Europe Market Value (US$ Mn), By End User 2022 to 2032
TABLE 86: Japan Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 87: Japan Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 88: Japan Market Value (US$ Mn), By End User 2017 to 2021
TABLE 89: Japan Market Value (US$ Mn), By End User 2022 to 2032
TABLE 90: APEJ Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 91: Source: FactMR, 2021APEJ Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 92: APEJ Market Value (US$ Mn), By End User 2017 to 2021
TABLE 93: APEJ Market Value (US$ Mn), By End User 2022 to 2032
TABLE 94: MEA Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 95: MEA Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 96: MEA Market Value (US$ Mn), By End User 2017 to 2021
TABLE 97: MEA Market Value (US$ Mn), By End User 2022 to 2032
TABLE 98: US Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 99: US Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 100: US Market Value (US$ Mn), By End User 2017 to 2021
TABLE 101: US Market Value (US$ Mn), By End User 2022 to 2032
TABLE 102: Canada Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 103: Canada Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 104: Canada Market Value (US$ Mn), By End User 2017 to 2021
TABLE 105: Canada Market Value (US$ Mn), By End User 2022 to 2032
TABLE 106: Brazil Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 107: Brazil Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 108: Brazil Market Value (US$ Mn), By End User 2017 to 2021
TABLE 109: Brazil Market Value (US$ Mn), By End User 2022 to 2032
TABLE 110: Mexico Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 111: Mexico Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 112: Mexico Market Value (US$ Mn), By End User 2017 to 2021
TABLE 113: Mexico Market Value (US$ Mn), By End User 2022 to 2032
TABLE 114: Argentina Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 115: Argentina Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 116: Argentina Market Value (US$ Mn), By End User 2017 to 2021
TABLE 117: Argentina Market Value (US$ Mn), By End User 2022 to 2032
TABLE 118: Germany Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 119: Germany Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 120: Germany Market Value (US$ Mn), By End User 2017 to 2021
TABLE 121: Germany Market Value (US$ Mn), By End User 2022 to 2032
TABLE 122: UK Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 123: UK Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 124: UK Market Value (US$ Mn), By End User 2017 to 2021
TABLE 125: UK Market Value (US$ Mn), By End User 2022 to 2032
TABLE 126: France Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 127: France Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 128: France Market Value (US$ Mn), By End User 2017 to 2021
TABLE 129: France Market Value (US$ Mn), By End User 2022 to 2032
TABLE 130: Spain Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 131: Spain Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 132: Spain Market Value (US$ Mn), By End User 2017 to 2021
TABLE 133: Spain Market Value (US$ Mn), By End User 2022 to 2032
TABLE 134: Italy Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 135: Italy Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 136: Italy Market Value (US$ Mn), By End User 2017 to 2021
TABLE 137: Italy Market Value (US$ Mn), By End User 2022 to 2032
TABLE 138: Nordic Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 139: Nordic Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 140: Nordic Market Value (US$ Mn), By End User 2017 to 2021
TABLE 141: Nordic Market Value (US$ Mn), By End User 2022 to 2032
TABLE 142: Japan Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 143: Japan Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 144: Japan Market Value (US$ Mn), By End User 2017 to 2021
TABLE 145: Japan Market Value (US$ Mn), By End User 2022 to 2032
TABLE 146: China Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 147: China Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 148: China Market Value (US$ Mn), By End User 2017 to 2021
TABLE 149: China Market Value (US$ Mn), By End User 2022 to 2032
TABLE 150: India Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 151: India Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 152: India Market Value (US$ Mn), By End User 2017 to 2021
TABLE 153: India Market Value (US$ Mn), By End User 2022 to 2032
TABLE 154: Malaysia Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 155: Malaysia Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 156: Malaysia Market Value (US$ Mn), By End User 2017 to 2021
TABLE 157: Malaysia Market Value (US$ Mn), By End User 2022 to 2032
TABLE 158: Thailand Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 159: Thailand Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 160: Thailand Market Value (US$ Mn), By End User 2017 to 2021
TABLE 161: Thailand Market Value (US$ Mn), By End User 2022 to 2032
TABLE 162: Singapore Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 163: Singapore Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 164: Singapore Market Value (US$ Mn), By End User 2017 to 2021
TABLE 165: Singapore Market Value (US$ Mn), By End User 2022 to 2032
TABLE 166: Australia Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 167: Australia Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 168: Australia Market Value (US$ Mn), By End User 2017 to 2021
TABLE 169: Australia Market Value (US$ Mn), By End User 2022 to 2032
TABLE 170: GCC Countries Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 171: GCC Countries Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 172: GCC Countries Market Value (US$ Mn), By End User 2017 to 2021
TABLE 173: GCC Countries Market Value (US$ Mn), By End User 2022 to 2032
TABLE 174: South Africa Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 175: South Africa Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 176: South Africa Market Value (US$ Mn), By End User 2017 to 2021
TABLE 177: South Africa Market Value (US$ Mn), By End User 2022 to 2032
TABLE 178: Nigeria Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 179: Nigeria Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 180: Nigeria Market Value (US$ Mn), By End User 2017 to 2021
TABLE 181: Nigeria Market Value (US$ Mn), By End User 2022 to 2032
TABLE 182: Israel Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 183: Israel Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 184: Israel Market Value (US$ Mn), By End User 2017 to 2021
TABLE 185: Israel Market Value (US$ Mn), By End User 2022 to 2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
FIG. 1: Global Market Value (US$ Mn), 2017 to 2021: Global Breast Cancer Value), 2022 to 2032 Value (US$ Mn)
FIG. 2: Market Value (US$ Mn) Forecast, 2022 to 2032
FIG. 3: Global Market Value (US$ Mn) and Y-o-Y, 2017 to 2032
FIG. 4: Global BRCA Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 5: Global BRCA Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 6: Global BRCA Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 7: Global ER & PR Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 8: Global ER & PR Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 9: Global ER & PR Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 10: Global CEA Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 11: Global CEA Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 12: Global CEA Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 13: Global KRAS Mutation Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 14: Global KRAS Mutation Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 15: Global KRAS Mutation Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 16: Global HER 2 Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 17: Global HER 2 Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 18: Global HER 2 Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 19: Global PSA Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 20: Global PSA Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 21: Global PSA Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 22: Global CA Test Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 23: Global CA Test Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 24: Global CA Test Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 25: Global EGFR Mutation Test Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 26: Global EGFR Mutation Test Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 27: Global EGFR Mutation Test Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 28: Global Immunohistochemistry Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 29: Global Immunohistochemistry Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 30: Global Immunohistochemistry Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 31: Global Others Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 32: Global Others Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 33: Global Others Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 34: Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 35: Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 36: Global Hospital Associated Labs Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 37: Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 38: Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 39: Global Independent Diagnostic Laboratories Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 40: Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 41: Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 42: Global Cancer Research Institutes Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 43: Global Others Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 44: Global Others Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 45: Global Others Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 46: North America Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 47: North America Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 48: North America Market Value (US$ Mn), By End User 2017 to 2021
FIG. 49: North America Market Value (US$ Mn), By End User 2022 to 2032
FIG. 50: Latin America Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 51: Latin America Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 52: Latin America Market Value (US$ Mn), By End User 2017 to 2021
FIG. 53: Latin America Market Value (US$ Mn), By End User 2022 to 2032
FIG. 54: Europe Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 55: Europe Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 56: Europe Market Value (US$ Mn), By End User 2017 to 2021
FIG. 57: Europe Market Value (US$ Mn), By End User 2022 to 2032
FIG. 58: Japan Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 59: Japan Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 60: Japan Market Value (US$ Mn), By End User 2017 to 2021
FIG. 61: Japan Market Value (US$ Mn), By End User 2022 to 2032
FIG. 62: APEJ Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 63: APEJ Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 64: APEJ Market Value (US$ Mn), By End User 2017 to 2021
FIG. 65: APEJ Market Value (US$ Mn), By End User 2022 to 2032
FIG. 66: MEA Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 67: MEA Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 68: MEA Market Value (US$ Mn), By End User 2017 to 2021
FIG. 69: MEA Market Value (US$ Mn), By End User 2022 to 2032
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the breast cancer diagnostics industry worth?
As of 2022, the market for breast cancer diagnostics will reach nearly US$ 4 Bn
At what rate will the breast cancer diagnostics industry grow from 2022-2032?
The breast cancer diagnostics industry is expected to surpass a CAGR of 7% from 2022-2032.
How much is the breast cancer diagnostics market like to be valued by 2032?
The breast cancer diagnostics market is expected to reach nearly US$ 7.9 Bn by 2032
What are the key trends driving breast cancer diagnostics sales?
Availability of multiple tests along with accurate results and technological advancements are the key trends driving breast cancer diagnostics sales.
Who are the prominent breast cancer diagnostics market players?
Bio-Rad Laboratories Inc, Illumina Inc, Biocept Inc, Epigenomics AG, AstraZeneca plc, Myriad Genetics Inc and Quest Diagnostics Incorporated are prominent breast cancer diagnostics market players.
Which type of test is expected to hold the highest share for sales?
CEA test are expected to hold more than 45% market share for Breast Cancer Diagnostics.
Which type of course is expected to hold the highest share for sales?
Hospital based labs are expected to hold more than 50% market share for breast cancer diagnostics market.
How much is the North America breast cancer diagnostics industry worth?
The breast cancer diagnostics industry is expected to possess nearly 45% market share throughout North America.
How much is the Asia Pacific breast cancer diagnostics industry worth?
The breast cancer diagnostics industry is expected to possess nearly 40% market share throughout Asia Pacific.
Breast Cancer Diagnostics Market